Next Article in Journal
Genomics and Immunomics in the Treatment of Urothelial Carcinoma
Previous Article in Journal
Hamartochondroma Pleural Lesion Mimicking Liposarcoma: A Case Report
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 29
Issue 5
10.3390/curroncol29050282
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer

by
Oskar Ragnarsson
1,*,
Marta Piasecka
1 and
Andreas Hallqvist
2
1
Department of Endocrinology, Sahlgrenska University Hospital, SE-41302 Gothenburg, Sweden
2
Department of Oncology, Sahlgrenska University Hospital, SE-41302 Gothenburg, Sweden
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3494-3498; https://doi.org/10.3390/curroncol29050282
Submission received: 22 March 2022 / Revised: 9 May 2022 / Accepted: 10 May 2022 / Published: 12 May 2022
Browse Figures
Review Reports Versions Notes

Abstract

Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six months later, all the cushingoid features had resolved, and s-calcitonin had decreased from 580 pmol/L to 3.5 pmol/L (normal < 3). After further 6 months, s-calcitonin had normalized (1.5 pmol/L), and radiological evaluation showed a profound tumour volume reduction. We are aware of two other cases where treatment with selpercatinib has also been successful. Thus, selpercatinib may be a promising treatment alternative in patients with ectopic Cushing’s syndrome due to medullary thyroid cancer, especially when other treatment options are ineffective or not tolerated.
Keywords: medullary thyroid cancer; ectopic Cushing’s syndrome; paraneoplastic syndrome; hypercortisolism medullary thyroid cancer; ectopic Cushing’s syndrome; paraneoplastic syndrome; hypercortisolism

Share and Cite

MDPI and ACS Style

Ragnarsson, O.; Piasecka, M.; Hallqvist, A. Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Curr. Oncol. 2022, 29, 3494-3498. https://doi.org/10.3390/curroncol29050282

AMA Style

Ragnarsson O, Piasecka M, Hallqvist A. Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Current Oncology. 2022; 29(5):3494-3498. https://doi.org/10.3390/curroncol29050282

Chicago/Turabian Style

Ragnarsson, Oskar, Marta Piasecka, and Andreas Hallqvist. 2022. "Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer" Current Oncology 29, no. 5: 3494-3498. https://doi.org/10.3390/curroncol29050282

APA Style

Ragnarsson, O., Piasecka, M., & Hallqvist, A. (2022). Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer. Current Oncology, 29(5), 3494-3498. https://doi.org/10.3390/curroncol29050282

Article Metrics

Back to TopTop